Astellas settles False Claims Act suit over Mycamine for $7.3M

Published



PHILADELPHIA (Legal Newsline) – A $7.3 million settlement has been reached with drugmaker Astellas Pharma US Inc. over claims that it violated the False Claims Act by illegally marketing the antifungal drug Mycamine to children.

The settlement was announced Wednesday by a team of whistleblower lawyers from Philadelphia-based Sheller P.C.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.


Tag:

Law